Buckingham Capital Management Inc. cut its holdings in Medtronic plc. (NYSE:MDT) by 4.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,097 shares of the medical technology company’s stock after selling 782 shares during the period. Buckingham Capital Management Inc.’s holdings in Medtronic were worth $1,407,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Captrust Financial Advisors bought a new stake in shares of Medtronic during the 2nd quarter valued at $384,000. Wesbanco Bank Inc. raised its position in shares of Medtronic by 3.1% during the 2nd quarter. Wesbanco Bank Inc. now owns 10,170 shares of the medical technology company’s stock valued at $903,000 after purchasing an additional 308 shares during the period. Dupont Capital Management Corp raised its position in shares of Medtronic by 28.8% during the 2nd quarter. Dupont Capital Management Corp now owns 74,052 shares of the medical technology company’s stock valued at $6,572,000 after purchasing an additional 16,562 shares during the period. Chilton Investment Co. LLC raised its position in shares of Medtronic by 6.1% during the 2nd quarter. Chilton Investment Co. LLC now owns 26,842 shares of the medical technology company’s stock valued at $2,382,000 after purchasing an additional 1,538 shares during the period. Finally, Moors & Cabot Inc. raised its position in shares of Medtronic by 0.4% during the 2nd quarter. Moors & Cabot Inc. now owns 43,227 shares of the medical technology company’s stock valued at $3,842,000 after purchasing an additional 178 shares during the period. Institutional investors and hedge funds own 81.74% of the company’s stock.

In other Medtronic news, EVP Bryan C. Hanson sold 16,000 shares of Medtronic stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.02, for a total value of $1,264,320.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 48,000 shares of company stock valued at $3,837,920 over the last three months. Corporate insiders own 0.31% of the company’s stock.

Several analysts have recently commented on the stock. SunTrust Banks restated a “buy” rating and set a $96.00 price objective on shares of Medtronic in a research report on Friday, November 3rd. BMO Capital Markets reaffirmed an “outperform” rating and set a $89.00 target price (down from $92.00) on shares of Medtronic in a research note on Tuesday, October 10th. Stifel Nicolaus raised their target price on shares of Medtronic from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Wednesday, November 22nd. Needham & Company LLC cut their target price on shares of Medtronic from $95.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, October 10th. Finally, Oppenheimer reaffirmed a “buy” rating and set a $94.00 target price on shares of Medtronic in a research note on Wednesday, November 22nd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Medtronic presently has an average rating of “Hold” and an average price target of $88.57.

Medtronic plc. (NYSE MDT) opened at $81.54 on Friday. Medtronic plc. has a 52 week low of $69.35 and a 52 week high of $89.72. The company has a market cap of $110,280.00, a price-to-earnings ratio of 22.40, a price-to-earnings-growth ratio of 2.25 and a beta of 1.00. The company has a quick ratio of 2.05, a current ratio of 2.40 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.08. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The business had revenue of $7.05 billion during the quarter, compared to analysts’ expectations of $7.05 billion. During the same period last year, the company posted $1.12 EPS. The business’s revenue was down 4.0% on a year-over-year basis. sell-side analysts anticipate that Medtronic plc. will post 4.77 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 19th. Shareholders of record on Friday, December 29th will be paid a $0.46 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.26%. Medtronic’s payout ratio is currently 50.55%.

COPYRIGHT VIOLATION WARNING: This piece was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://theolympiareport.com/2017/12/24/buckingham-capital-management-inc-sells-782-shares-of-medtronic-plc-mdt.html.

Medtronic Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.